RESOURCES

Eurofins DiscoverX’s KILR^®️ cytotoxicity assay platform accurately measures the killing of antigen-expressing target cells in co-culture with immune effector cells.

Lung cancer is the leading cause of cancer-related deaths worldwide, with non-small cell lung carcinoma (NSCLC) accounting for 85% of cases and associated with poor prognosis.

Accelerate Your Drug Discovery with Our State-of-the-Art Chemistry Services

A novel affinity-based screening approach using the Spectral Shift (SpS) technology was developed at Eurofins Discovery for hit finding programs.

Understanding a drug’s mechanism of action and potential side effects is vital for drug discovery. This study demonstrates the utility of KINOMEscan^®️, a high-throughput screening platform, to evaluate fifteen FDA-approved or clinical-stage BTK inhibitors.

Prediction of ADMET properties and off-target liabilities improves small molecule drug discovery efficiency. The EMERALD database, containing over 90,000 unique compounds and millions of experimental data points, provides a solid foundation for AI/ML tool development.

Two hot and emerging areas in drug discovery include the E3 ligases in targeted protein degradation (TPD) and SRC homology 2 (SH2) domain-containing proteins.

GPCR-based peptide therapeutics, particularly those targeting GLP-1, GIP, and glucagon receptors, offer tremendous potential in combating the global obesity crisis.

The FDA ICH S1B (R1) guidance have introduced a Weight of Evidence (WoE) approach for evaluating human carcinogenic risk in drug development.

A leading cause of drug attrition, warnings and market withdrawals is drug mediated hepatotoxicity resulting from biotransformation.

Developing a cell-based model using iPSC-derived microglia introduces an alternative method to animal cell models and immortalized cell lines that is more physiologically relevant to a patient-specific context.

Drug-induced Liver Injury (DILI) remains a major obstacle in drug development. Despite the use of various models, DILI continues to lead to drug attrition, post-market withdrawals, and safety warnings. Recent advancements in 3D culture of PHHs as spheroids have shown promise in overcoming these limitations.